Latest Biotech News

Parabilis Medicines priced an upsized $670 million IPO, securing what is described as the largest biotech IPO on record for a newly public company. The oncology-focused developer is also raising...

Sanofi stopped its Phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent monitoring board determined the trial was unlikely to...

Merck and Gilead reported positive results from two Phase 3 trials supporting a combination regimen designed to become the first weekly oral HIV pill. The approach pairs Merck’s islatravir with...

Verge Labs partnered with Tenacia Biotechnology to identify new CNS drug targets using Verge’s foundation models and multimodal patient datasets. The collaboration leverages more than 12,000 brain...

SonoThera raised $125 million in a Series B to advance an ultrasound-based non-viral gene delivery platform toward clinical development. The funding includes participation from venture firms and...

Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, acquiring a degrader antibody conjugate platform. The acquisition is intended to expand J&J’s therapeutic toolkit around...

Pfizer CEO Albert Bourla said the company is reassessing its planned investments in Germany amid policy proposals aimed at reducing drug spending. Reuters reported Bourla raised concerns in a...

Researchers engineered a CRISPR-based cancer approach designed to selectively destroy targeted cells using a specialized “destroyer” enzyme concept rather than classic gene-editing. The work,...

Beren Therapeutics raised $300 million through new financings as it prepares for an FDA decision later this fall for its rare disease drug candidate. The capital raise is explicitly positioned to...

Sanofi halted its Phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent monitoring board concluded the antibody was unlikely to...

Parabilis Medicines set a record for biotech going public by pricing a $670 million IPO at $20 per share, topping prior 2026 listings in the sector. The oncology-focused company—formerly Fog...

SonoThera raised $125 million in a Series B to advance its ultrasound-based gene therapy platform into the clinic. The company’s approach uses microbubbles activated by ultrasound to enhance...

GSK agreed to acquire Nuvalent for about $10.6 billion in cash, securing two late-stage lung cancer medicines under FDA review: zidesamtinib (ROS1) and neladalkib (ALK). The acquisition reinforces...

Incyte agreed to acquire Vega Therapeutics for up to $2 billion, aiming to expand its hematology pipeline with VGA039, a Phase III von Willebrand disease candidate. The deal adds a monoclonal...

Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, acquiring a degrader antibody conjugate (DAC) platform along with development capabilities. The transaction adds to the market...

Merck and Gilead reported mixed results across two Phase 3 areas: Gilead’s Trodelvy missed in first-line lung cancer, while a once-weekly oral HIV combination program showed success. The Trodelvy...

JP Morgan upgraded Illumina to Overweight from Neutral and set a $185 price target, citing growing visibility into demand for sequencers and consumables. The analyst highlighted customer...

African and European regulators are preparing trials for Bundibugyo Ebola vaccines and therapeutic options in the Democratic Republic of the Congo and Uganda. Reporting indicates multiple products...

Geneoscopy said CMS added its ColoSense stool-based RNA test to the National Coverage Determination for colorectal cancer screening. The update creates a coverage framework that supports future...

Sanofi has stopped a Phase 3 trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent monitoring board concluded the therapy was unlikely to achieve...